Antidiabetic Screening of Commercial Botanical Products in 3T3-L1 Adipocytes and db/db Mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Numerous botanicals are purported to improve glucose metabolism and diabetic risk factors with varying degrees of supportive evidence. We investigated 203 commercially available botanical products representing 90 unique botanical species for effects on lipogenic activity in differentiating 3T3-L1 adipocytes. Anti-inflammatory activity of 21 of these products was further assessed in tumor necrosis factor alpha (TNFalpha)-stimulated, mature 3T3-L1 adipocytes. From these results, rho-isoalpha acids, Acacia nilotica bark, fennel, and wasabi were tested in the db/db mouse model. Fifty-nine percent of the 90 unique botanicals increased adipogenesis as did the standard troglitazone relative to the solvent controls. Botanical species with the greatest percentage of positive products were Centella asiatica, Panax quinquefolius, and Phyllanthus amarus at 100%, Vitis vinifera at 80%, Humulus lupulus at 71%, Aloe barbadensis at 66%, and Momordica charantia, Phaseolus vulgaris, and Punica granatum at 60%. All 21 subset samples inhibited TNFalpha-stimulated free fatty acid release and attenuated TNFalpha inhibition of adiponectin secretion. Both rho-isoalpha acids and A. nilotica reduced nonfasting glucose in the db/db mouse model, whereas A. nilotica also decreased nonfasting insulin levels. A post hoc analysis of the screening results indicated that the positive predictive value of the lipogenesis assay alone was 72%, while adding the criterion of a positive response in the anti-inflammatory assays increased this figure to 82%. Moreover, this large-scale evaluation demonstrates that antidiabetic, in vitro efficacy of botanicals is more a function of manufacturing or quality control differences than the presence of marker compounds and further underscores the need to develop functional as well as analytical bases for standardization of dietary supplements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 1×
“19 Drugs to treat IR and T2D exist, but they often lose effectiveness over time 20 and have side effects such as liver toxicity and weight gain.”
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Projection of Diabetes Burden Through 2050
Boyle, J. P., Honeycutt, A. A., Narayan, K. M. V., Hoerger, T. J., Geiss, L. S., Chen, H., & Thompson, T. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1936 · Cited by 1,004 · cited 1×
“and world population, and an analysis of trend data suggests that the burden will continue to increase.(6) In light of the tremendous cost of T2D, in terms of both human suffering and monetary resources, it is highly desirable to have additional agents to support therapeutic treatment or for the formulation of special…”
Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study
Villegas, R., Gao, Y.-T., Yang, G., Li, H.-L., Elasy, T. A., Zheng, W., & Shu, X. O. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.1.162 · Cited by 393
Secretory factors from human adipose tissue and their functional role
Hauner, H. (2005) · Proceedings of the Nutrition Society · doi:10.1079/pns2005428 · Cited by 391 · cited 1×
“More than 100 secretory factors have been described as being produced and released by adipocytes.(16) Through paracrine and autocrine functioning, adipocytes are capable of influencing multiple physiological and pathophysiological processes.”
Bajaj, M., Suraamornkul, S., Romanelli, A., Cline, G. W., Mandarino, L. J., Shulman, G. I., & DeFronzo, R. A. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3148 · Cited by 181 · cited 12×
“Elevated plasma FFA levels are implicated as factors that contribute to a number of signs associated with T2D; moreover, it has been demonstrated that inhibitors of fatty acid release from adipose tissue improve insulin sensitivity and ameliorate at least some of the symptoms of T2D.(43) The high cost of the follow-up…”
InfluentialImportance of TNFα and neutral lipases in human adipose tissue lipolysis
Langin, D., & Arner, P. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.08.003 · Cited by 140
Cited by
Rosemary Extract as a Potential Anti-Hyperglycemic Agent: Current Evidence and Future Perspectives
Naimi, M., Vlavcheski, F., Shamshoum, H., & Tsiani, E. (2017) · Nutrients · doi:10.3390/nu9090968 · Cited by 119
“An increase in glucose uptake and intracellular lipid levels was seen in 3T3-L1 adipocytes treated with RE (50 μg/mL) (Table 4) [42].”
BackgroundMango fruit peel and flesh extracts affect adipogenesis in 3T3-L1 cells
Taing, M.-W., Pierson, J.-T., Hoang, V. L. T., Shaw, P. N., Dietzgen, R. G., Gidley, M. J., Roberts-Thomson, S. J., & Monteith, G. R. (2012) · Food & Function · doi:10.1039/c2fo30073g · Cited by 38
Dushkin, M., Khrapova, M., Kovshik, G., Chasovskikh, M., Menshchikova, E., Trufakin, V., Shurlygina, A., & Vereschagin, E. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-33 · Cited by 25
Metadata
- Authors
- Babish, J. G., Pacioretty, L. M., Bland, J. S., Minich, D. M., Hu, J., & Tripp, M. L.
- Venue
- Journal of Medicinal Food
- Publisher
- SAGE Publications
- Published
- 2010-06
- Volume
- 13
- Issue
- 3
- Pages
- 535-547
- ISSN
- 1096-620X (ISSN-L)
- 1557-7600
- OpenAlex
- W2085692257
- Cited by
- 36
- References
- 8
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.